MétaCan
Menu
Back to cohort
Record W4393041131 · doi:10.1111/trf.17777

Quality of life and <scp>cost‐effectiveness</scp> of convalescent plasma compared to standard care for hospitalized <scp>COVID</scp>‐19 patients in the <scp>CONCOR</scp>‐1 trial

2024· article· en· W4393041131 on OpenAlexafffundabout
Preston Tse, Jiajun Yan, Yang Liu, Erin Jamula, Nancy M. Heddle, Renée Bazin, Nancy Robitaille, Richard J. Cook, Alexis F. Turgeon, Dean Fergusson, Marshall J. Glesby, Kent Cadogan Loftsgard, Melissa M. Cushing, Michaël Chassé, Nick Daneman, Andrés Finzi, Bruce S. Sachais, Philippe Bégin, Jeannie Callum, Donald M. Arnold, Feng Xie

Bibliographic record

VenueTransfusion · 2024
Typearticle
Languageen
FieldMedicine
TopicLong-Term Effects of COVID-19
Canadian institutionsQueen's UniversityUniversité de MontréalUniversity of TorontoCanadian Patient Safety InstituteKingston Health Sciences CentreUniversity of OttawaCommunity Based Research CentreCentre Hospitalier de l’Université de MontréalUniversité LavalUniversity of WaterlooMcMaster UniversityCentre Hospitalier Universitaire Sainte-JustineHealth Sciences CentreOttawa HospitalHéma-QuébecSunnybrook Health Science CentreCanadian Blood ServicesImpact
FundersCanadian Institutes of Health Research
KeywordsMedicineRandomizationRandomized controlled trialPopulationConvalescent plasmaClinical trialQuality of life (healthcare)Emergency medicineCoronavirus disease 2019 (COVID-19)Internal medicineDiseaseEnvironmental health

Abstract

fetched live from OpenAlex

BACKGROUND: The CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID-19 patients. This study evaluates the cost-effectiveness of convalescent plasma and its impact on quality-of-life to provide insight into its potential as an alternative treatment in resource-constrained settings. METHODS: Individual patient data on health outcomes and resource utilization from the CONCOR-1 trial were used to conduct the analysis from the Canadian public payer's perspective with a time horizon of 30 days post-randomization. Baseline and 30-day EQ-5D-5L were measured to calculate quality-adjusted survival. All costs are presented in 2021 Canadian dollars. The base case assessed the EQ-5D-5L scores of hospitalized inpatients reporting at both timepoints, and a utility score of 0 was assigned for patients who died within 30 days. Costs for all patients enrolled were used. The sensitivity analysis utilizes EQ-5D-5L scores from the same population but only uses costs from this population. RESULTS: 940 patients were randomized: 627 received CCP and 313 received standard care. The total costs were $28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and standard care arms respectively. EQ-5D-5L scores were 0.61 in both arms (p = .85) at baseline. At 30 days, EQ-5D-5L scores were 0.63 and 0.64 for patients in the convalescent plasma and standard care arms, respectively (p = .46). The incremental cost was $4458 and the incremental quality-adjusted life day was -0.078. DISCUSSION: Convalescent plasma was less effective and more costly than standard care in treating hospitalized COVID-19.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.010
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.213
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.010
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.030
GPT teacher head0.341
Teacher spread0.311 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2024
Admission routes3
Has abstractyes

Explore more

Same venueTransfusionSame topicLong-Term Effects of COVID-19French-language works237,207